Cancer Research · us
Blocking Cancer Cells’ Growth Signals: A Combined Radiation Strategy for Leptomeningeal Metastasis Enters Human Trials
After invading the cerebrospinal fluid, cancer cells may continue to grow through CXCL1–CXCR2 signaling and become less responsive to radiation therapy. Researchers found effects from blocking this pathway in mice and have launched an early clinical trial of SX-682 combined with proton radiation therapy.
When cancer cells spread to the leptomeninges surrounding the brain and spinal cord and to the cerebrospinal fluid, treatment must address disease extending throughout the area surrounding the central nervous system. Although proton craniospinal irradiation offers a treatment option, patients’ responses vary. A research team at Memorial Sloan Kettering Cancer Center (MSK) has identified a signaling pathway associated with this variation and advanced a strategy to block it into human trials.
A research summary released by MSK on October 9 described the study, which was published in *Science Translational Medicine* on September 23. The team analyzed patients’ cerebrospinal fluid before and after proton craniospinal irradiation and found that higher pretreatment concentrations of the chemokine CXCL1 were associated with poorer treatment responses; higher pretreatment CXCR2 expression was also associated with poorer overall survival. These associations provided leads for further investigation, but are not yet sufficient to establish that testing these molecules can accurately predict treatment outcomes for individual patients.
CXCL1 is a protein that transmits signals between cells and acts through the receptor CXCR2. To clarify its role in the disease, researchers separately removed Cxcl1 from metastatic cancer cells and host cells in mouse models. Removing Cxcl1 from the cancer cells themselves inhibited tumor growth within the leptomeninges, while removing the same gene from host cells did not produce the same effect. This supports the role of signals produced by cancer cells as an important component in sustaining the growth of metastatic lesions.
The team then administered a CXCR2 antagonist intrathecally, delivering it into the space containing cerebrospinal fluid. In preclinical models, blocking this receptor both inhibited tumor growth and made cancer cells more sensitive to craniospinal irradiation. MSK stated that the combined treatment was more effective than either treatment alone, providing experimental evidence for improving responses to radiation therapy.
Following this line of research, MSK has launched a phase Ib trial testing SX-682 combined with proton craniospinal irradiation. According to the institution’s trial page, SX-682 is a dual inhibitor of CXCR1 and CXCR2; the study registration number is NCT07814352, and the associated cancer types listed on the page include non-small cell lung cancer and melanoma. This trial will bring the treatment concept proposed by the animal research into testing in patients.
However, the experiments with an intrathecal antagonist in mice cannot be directly equated with the efficacy of SX-682 in humans. The information released so far does not provide human results for this combined therapy, and its safety, appropriate dose, and clinical benefit remain to be established. MSK’s suggestion that radiation doses might eventually be lowered to reduce side effects also remains a research hypothesis. The significance of this advance lies in identifying a biological mechanism that can be targeted and beginning to test whether doing so can change treatment responses in a disease that is difficult to treat.